TTY Biopharm Company Limited (TPEX:4105)

Market Cap	20.81B +11.2%
Revenue (ttm)	6.50B +11.6%
Net Income	1.79B +59.9%
EPS	7.19 +60.1%
Shares Out	248.65M
PE Ratio	11.64
Forward PE	14.11
Dividend	4.20 (5.02%)
Ex-Dividend Date	Mar 27, 2025

Volume	638,457
Average Volume	728,860
Open	84.10
Previous Close	84.10
Day's Range	83.10 - 84.40
52-Week Range	66.20 - 87.00
Beta	0.03
RSI	48.02
Earnings Date	Mar 13, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through the Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2024, TTY Biopharm Company's revenue was 5.89 billion, an increase of 7.05% compared to the previous year's 5.51 billion. Earnings were 1.45 billion, an increase of 28.45%.